Disease relevance of Medemycin

• Midecamycin, an acetoxy-substituted macrolide antibiotic, was tested against gram-positive and gram-negative bacteria [1].
• A survey of five Nocardia spp. with respect to susceptibility towards three macrolides (erythromycin, rokitamycin, and midecamycin) showed that the Nocardia spp. have different susceptibility profiles [2].
• A macrolide 3-O-acyltransferase gene from the midecamycin-producing species Streptomyces mycarofaciens [3].
• In vitro activity of midecamycin diacetate against Mycoplasma pneumoniae and Chlamydia pneumoniae [4].
• Effects of the macrolide antibiotic, midecamycin, on Staphylococcus aureus product-induced Th2 cytokine response in patients with atopic dermatitis [5].

High impact information on Medemycin

• 3. Neither ivermectin nor midecamycin removed FKBP12 from RyRs [6].
• Effects of ivermectin and midecamycin on ryanodine receptors and the Ca2+-ATPase in sarcoplasmic reticulum of rabbit and rat skeletal muscle [6].
• Hexobarbital sleeping time was unaffected by preadministration of josamycin or midecamycin (4 mmoles . kg-1 p.o.) 2 hr earlier; the in vitro activity of hexobarbital hydroxylase was not inhibited by 0.3 mM josamycin or midecamycin [7].
• Acute hepatitis during hypersensitivity syndrome due to midecamycin [8].
• Airborne allergic contact dermatitis from kitasamycin and midecamycin [9].

Chemical compound and disease context of Medemycin

• 9,3"-Di-O-acetyl midecamycin (Mom) showed in vitro antibacterial activity against clinical isolates of Staphylococcus aureus and was effective against some of the strans resistant to erythromycin (Em) and josamycin (Jm) [10].
• The postantibiotic effects (PAEs) of macrolide antibiotics, such as midecamycin acetate (Miocamycin, MOM), erythromycin (EM), josamycin (JM) and clarithromycin (CAM), on Staphylococcus aureus and the ultrastructure of the pathogen during the postantibiotic phase were investigated [11].
• Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part VI-2. Acute toxicity in infant rats in comparison with young adult rats [12].
• Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miokamycin). Part I-1. Acute toxicity in mice [13].
• For the purpose of studying therapy for pseudomonas infection, the synergistic effect of carbenicillin and midecamycin or 9,3''-di-O-acetyl midecamycin on Pseudomonas aeruginosa were studied in vitro and in vivo [14].

Biological context of Medemycin

• Direct acetylation of midecamycin (1) led to the formation of the 3'',4''-positional isomer (6) [15].
• A 2.4 kb fragment containing the midecamycin polyketide synthase genes (mps) was subcloned from the preliminary clone pCN8B12 out of the genomic library of midecamycin-producing strain S. mycarofaciens 1748, by using the homologous DNA of the actinorhodin polyketide synthase gene (act I) as hybridization probe [16].
• A study of esterase--its application to biotransformation of midecamycin derivatives [17].
• Plasmid DNA in midecamycin-producing strain Streptomyces mycarofaciens 1748 [18].
• Effect of midecamycin acetate on gastrointestinal motility in humans [19].

Anatomical context of Medemycin

• Influence of midecamycin acetate, a new macrolide antibiotic, on bactericidal action of human polymorphonuclear leukocytes [20].
• Esterases of intestinal mucosa and liver from human and rat were used to study the biotransformation of midecamycin derivatives [17].
• Midecamycin and 9,3''-di-O-acetyl midecamycin were effective against spheroplasts of P. aeruginosa induced by carbenicillin treatment [14].

Associations of Medemycin with other chemical compounds

• Miocamycin (MOM) is a derivative of midecamycin and is metabolized into 4 main metabolites of Mb1, Mb2, Mb6 and Mb12 [21].
• Our studies were done to elucidate the action of a 14-membered-ring macrolide (erythromycin; EM) and a 16-membered-ring macrolide (midecamycin; MDM) on guanosine diphospho-d-mannose dehydrogenase (GDP-mannose dehydrogenase; GMD), one of the constituents of bacterial biofilm that is known to produce alginate [22].
• However, cloxacillin, cyclosporin A and midecamycin inhibited BSEP, and cyclosporin A and midecamycin inhibited MRP2 with an inhibition constant close to the clinical concentration [23].

Gene context of Medemycin

• Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part VI-1. Acute toxicity in infant mice in comparison with young adult mice [24].

Analytical, diagnostic and therapeutic context of Medemycin

• Western blots of terminal cisternae (TC), incubated for 15 min at 37 C with 40 microM ivermectin or midecamycin, showed normal amounts of FKBP12 [6].
• Transformation of the cloned DNA into the S. mycarofaciens blocked mutant 68 and into Streptomyces lividans TK24 resulted in the production of midecamycin-like substances by TLC and HPLC analyses [25].
• The promoter region of the midecamycin 4"-hydroxyl propionyltransferase gene (mpt) gene was reconstructed by PCR, and ligated with a fragment from the midecamycin producing strain (Streptomyces mycarofaciens var. 68) which contained fairly strong promoter activity (PLF) [26].

References